TY - JOUR
T1 - Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
AU - Aalbers, René
AU - Maleki-Yazdi, M Reza
AU - Hamilton, Alan
AU - Waitere-Wijker, Stella
AU - Zhao, Yihua
AU - Amatto, Valeria C
AU - Schmidt, Olaf
AU - Bjermer, Leif
PY - 2015
Y1 - 2015
N2 - Combining long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action. The optimal dose for the fixed-dose combination of the LAMA tiotropium and the LABA olodaterol needed to be determined. In this phase II trial, the dose response of tiotropium on top of olodaterol was investigated in a free-dose combination, while other phase II studies have explored different doses of olodaterol on top of tiotropium, with both drugs delivered using the Respimat(®) inhaler.
AB - Combining long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action. The optimal dose for the fixed-dose combination of the LAMA tiotropium and the LABA olodaterol needed to be determined. In this phase II trial, the dose response of tiotropium on top of olodaterol was investigated in a free-dose combination, while other phase II studies have explored different doses of olodaterol on top of tiotropium, with both drugs delivered using the Respimat(®) inhaler.
U2 - 10.1007/s12325-015-0239-8
DO - 10.1007/s12325-015-0239-8
M3 - Article
C2 - 26404912
SN - 0741-238X
VL - 32
SP - 809
EP - 822
JO - Advances in Therapy
JF - Advances in Therapy
IS - 9
ER -